Should you buy GRAIL stock now?
Yes, the technical signal for GRAIL is currently Buy. GRAIL trades at $0.00 as of Oct 26, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 6.505 with falling momentum (signal: 9.348); RSI is at 56.6 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for GRAIL stock?
There is currently no active analyst price target for GRAIL.
Is GRAIL a dividend stock?
No, GRAIL does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of GRAIL stock?
GRAIL is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 76.0%, which classifies the stock as Extremely speculative.
Is GRAIL overvalued?
GRAIL has the following valuation ratios: a P/S ratio of 35.8, a P/B ratio of 1.3.
Is GRAIL overbought?
No, GRAIL is not overbought. RSI is at 56.6 (neutral zone). The technical indicators show: RSI is at 56.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, MACD is positive, but momentum is falling.
When is the next GRAIL earnings report?
GRAIL reports its next earnings on November 4, 2026. The stock currently trades at $0.00.
Is GRAIL shorted?
Yes, GRAIL is shorted with 18.2% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying GRAIL stock?
No, insiders are not buying GRAIL shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 7 sales. On a net basis, 8,841,034 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 23,535,138 $ sold. Active sellers include Ofman Joshua J., Partridge Andrew John, Freidin Aaron and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is GRAIL a good stock?
Based on our total score, GRAIL is rated as a mediocre stock with a total score of 41 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 23/100, Quality: 3/100, Momentum: 99/100. Whether now is the time to buy is a separate question: the technical signal is Buy. Whether GRAIL is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for GRAIL stock?
The outlook for GRAIL based on current data: the next earnings report is due on Nov 4, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is GRAIL stock moving?
GRAIL is moving right now. The technical indicators show: short interest is 18.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can GRAIL go?
There is currently no active analyst price target for GRAIL. The stock has traded between $41.50 and $166.48 over the last 52 weeks. The price is 100.0% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can GRAIL fall?
We lack enough history to give a specific floor for GRAIL. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does GRAIL do?
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cance... The company belongs to the Healthcare sector, more specifically the Diagnostics & Research industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate GRAIL as an investment.
Did GRAIL raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from GRAIL. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is GRAIL making money or losing money?
No, GRAIL is currently not making money — the company is losing money with a negative profit margin of -237.0%, a substantial loss. That means the business loses money on every dollar of revenue. The operating margin (profit before interest and taxes) is also negative at -332.0% — so it is not just financing costs weighing on the result. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can GRAIL go bankrupt?
The bankruptcy risk of GRAIL is rated as elevated. Altman Z2 (a model for assessing financial distress) is -2.40 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 4 — which is average. Debt relative to equity is 19% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does GRAIL have a lot of debt?
No, GRAIL has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 19%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.